Hypogonadotropic hypogonadism 5 with or without anosmia is a rare genetic condition that affects puberty and fertility. People with this condition often have delayed or absent puberty, low sex hormone levels, and sometimes a reduced sense of smell. Features usually begin in adolescence and tend to be lifelong, though responses to treatment can vary. Many people with Hypogonadotropic hypogonadism 5 with or without anosmia do well with hormone therapy and fertility treatments. Life expectancy is generally typical, and care focuses on replacing hormones and supporting bone and reproductive health.
Overview
Hypogonadotropic hypogonadism 5 with or without anosmiaSymptoms
In hypogonadotropic hypogonadism 5 with or without anosmia, features include delayed or absent puberty and infertility. Males may have undescended testes; females may lack periods and breast development. Smell may be reduced or absent; signs appear at birth or adolescence.
Outlook and prognosis
Most people with hypogonadotropic hypogonadism 5 with or without anosmia improve with tailored hormone therapy, which supports puberty, sexual health, bone strength, and fertility planning. Outcomes vary by age at diagnosis and treatment response. Regular follow-up helps fine‑tune hormones and monitor long‑term health.
Causes and risk factors
Hypogonadotropic hypogonadism 5 with or without anosmia is due to a single-gene change affecting hormone and smell pathways, usually inherited or new. Risk factor for hypogonadotropic hypogonadism 5 is family history; lifestyle doesn’t cause it, though illness may affect severity.
Genetic influences
Genetics play a central role in hypogonadotropic hypogonadism 5 with or without anosmia. Inherited variants in specific genes disrupt hormone signals that trigger puberty and fertility. Patterns vary by gene; some families show autosomal dominant, recessive, or X-linked inheritance.
Diagnosis
Diagnosis relies on delayed puberty and smell testing, plus blood tests showing low sex hormones with low pituitary signals. MRI may assess olfactory structures and pituitary. Genetic diagnosis of Hypogonadotropic hypogonadism 5 with or without anosmia can confirm.
Treatment and drugs
Treatment for hypogonadotropic hypogonadism 5 with or without anosmia focuses on safely restoring hormones and supporting fertility goals. Care often includes tailored estrogen/testosterone replacement, puberty induction, and, when desired, fertility therapies like gonadotropin injections or pulsatile GnRH. Regular monitoring guides dosing, bone health, mood, and metabolic care.
Symptoms
For many, the first clues show up around puberty—changes start late or don’t progress as expected. Features vary from person to person and can change over time. Hypogonadotropic hypogonadism 5 with or without anosmia often affects puberty and fertility, and can include a reduced sense of smell in some. Families and teens sometimes ask about early features of Hypogonadotropic hypogonadism 5 with or without anosmia, such as delayed breast development or periods, small testes, sparse body hair, or trouble smelling odors.
Puberty starts late or stalls, with little breast growth or no first period in girls and women, and small testes, limited facial hair, or no voice deepening in boys and men. In Hypogonadotropic hypogonadism 5 with or without anosmia, these changes often do not progress without hormone treatment.
Some people with Hypogonadotropic hypogonadism 5 with or without anosmia have a reduced or absent sense of smell, while others smell normally. This difference is present from early life and may be subtle until someone notices they rarely detect odors.
In Hypogonadotropic hypogonadism 5 with or without anosmia, ovulation may not occur and sperm counts can be low. Many people can build a family with specialist care using hormones or assisted reproductive options.
Low estrogen or testosterone can reduce interest in sex and affect sexual function. Men may notice trouble with erections, and women may have vaginal dryness or discomfort.
How people usually first notice Hypogonadotropic hypogonadism 5 with or without anosmia?
People often first notice hypogonadotropic hypogonadism 5 with or without anosmia during puberty, when expected changes like breast development or testicular enlargement, voice deepening, growth spurts, and menstrual periods don’t start on time or remain very delayed. Some also realize they have a reduced or absent sense of smell (anosmia), which can be a clue doctors ask about when delayed puberty or low libido, fatigue, or infertility appear in the late teens or early adulthood. In infancy or childhood, less commonly, families or clinicians may spot undescended testes, micropenis, or poor growth, which can prompt earlier evaluation.
Types of Hypogonadotropic hypogonadism 5 with or without anosmia
Hypogonadotropic hypogonadism 5 with or without anosmia is a genetic condition that can show up in a few recognizable clinical variants. Broadly, symptoms are grouped into Kallmann syndrome (with reduced or absent smell) and normosmic forms (normal smell), with differences in puberty timing, fertility, and sometimes other features. Not everyone will experience every type. People may notice different sets of symptoms depending on their situation.
Kallmann variant
This type includes reduced or absent sense of smell (anosmia) alongside delayed or absent puberty and low sex hormone levels. Early symptoms of hypogonadotropic hypogonadism 5 may include lack of testicular growth or breast development during adolescence. Some may also have mild differences in facial structure or dental spacing, but not everyone.
Normosmic variant
Smell is normal, but puberty is delayed or does not progress due to low signals from the brain to the ovaries or testes. People may notice reduced libido, fatigue, or difficulty building muscle, and many discover this when evaluating infertility. In some, hormone replacement helps trigger and maintain sexual development.
Partial or intermittent
Signs of puberty start but remain incomplete, or fertility varies over time. One type may be strong for a while, then fade as another emerges. Some people respond briskly to pulsatile or standard hormone therapy, which can normalize cycles or sperm production.
Childhood-onset
Subtle signs appear in childhood, such as small testicular volume or absent mini-puberty in infants assigned male, or later lack of breast development in those assigned female. Growth is otherwise typical, so concerns often surface at expected puberty. Loved ones may recognize certain types sooner than the person experiencing them.
Adult-diagnosed
Puberty may have seemed delayed but eventually progressed, and symptoms come to light during family planning or evaluation of low energy and sexual function. Others are identified after stopping hormonal contraception when cycles do not resume. Keeping track of which type you experience most can help guide testing and treatment options.
What genetics can tell you about symptoms
Some people with Hypogonadotropic hypogonadism 5 have gene changes that disrupt brain signals to the ovaries or testes, leading to delayed or absent puberty, low sex hormones, infertility, low libido, and low energy. If the same genes also affect smell pathways, anosmia or reduced smell can appear.
Causes and risk factors
Hypogonadotropic hypogonadism 5 with or without anosmia is usually due to a change in a single gene that disrupts the brain hormones that trigger puberty. The gene change can be inherited from one or both parents, or it may happen for the first time in the family. Genes set the stage, but environment and lifestyle often decide how the story unfolds. A family history of delayed puberty, infertility, or a weak sense of smell is the main risk factor for hypogonadotropic hypogonadism 5, while illness, major weight loss, or very intense training can make hormone shortages more noticeable but do not cause it. Severity varies, so relatives with the same gene change can have different features, including normal smell in some and anosmia in others.
Environmental and biological risk factors
Most cases of hypogonadotropic hypogonadism 5 with or without anosmia begin before birth, so risks center on events in early development. If you’re looking into early symptoms of hypogonadotropic hypogonadism 5 with or without anosmia, it also helps to understand what might raise the chance that it occurs. Two people with the same exposure can react very differently—biology shapes the response. Below are environmental and biological factors researchers consider when assessing likelihood; direct links vary and evidence is still developing.
As fathers get older, the overall chance of some conditions present from birth increases slightly. This may modestly raise the likelihood of hypogonadotropic hypogonadism 5 with or without anosmia in a child. Most pregnancies with older fathers remain unaffected.
Pregnancy at an older age is linked with a higher overall risk of congenital differences. This could modestly increase the chance of hypogonadotropic hypogonadism 5 with or without anosmia. Most babies born to older mothers are healthy.
Poorly controlled diabetes early in pregnancy raises the risk of differences in fetal brain and craniofacial development. These areas are closely tied to hormone pathways and sense of smell. Risk depends on timing and how well diabetes is managed.
Uncontrolled thyroid disease in early pregnancy can affect fetal brain development. Disruption in these pathways may influence hormone signaling later in life.
Genetic risk factors
In Hypogonadotropic hypogonadism 5 with or without anosmia, inherited DNA changes can alter how hormone-releasing brain cells and smell pathways form before birth. Carrying a genetic change doesn’t guarantee the condition will appear. Different genes and inheritance patterns may be involved, which helps explain why smell loss occurs in some people and not others. These genetic factors also shape how early and how strongly puberty and fertility are affected.
Neuron development genes: Changes can disrupt the journey and survival of hormone-releasing neurons and smell nerve cells during early development. This can weaken the brain’s puberty signal (GnRH) and sometimes reduce or remove the sense of smell.
Mixed inheritance modes: Hypogonadotropic hypogonadism 5 with or without anosmia can run in families in a dominant or in a recessive way, depending on the gene involved. In some families one altered copy is enough, while in others both copies must carry a change.
Incomplete penetrance: Some relatives with the same DNA change have few or no signs. Others develop clear hormone deficiency or smell loss.
Variable expressivity: Features can range from delayed or stalled puberty to more complete hormone deficiency, even within one family. Smell can be normal, reduced, or absent.
Oligogenic influence: In some people, more than one rare gene change works together to raise risk or change severity. This can help explain differences between siblings.
De novo changes: A gene variant may arise for the first time in a child, with no prior family history. When this happens, the chance of it recurring in a sibling is usually low.
Copy-number variants: Missing or extra stretches of DNA that include relevant genes can produce the same hormone and smell pattern. These changes are less common than single-letter variants.
Smell pathway genes: Some variants mainly affect smell circuits, while others spare them. This is why Hypogonadotropic hypogonadism 5 with or without anosmia may or may not include anosmia.
Family history patterns: Clusters of delayed puberty, infertility, or absent smell in relatives can signal a hereditary risk. This can guide which genes to consider first in a family.
Genetic testing panels: Multi-gene or exome testing can find the genetic causes of Hypogonadotropic hypogonadism 5 with or without anosmia across many genes. Results can clarify inheritance and help estimate risks for future children.
Lifestyle risk factors
Hypogonadotropic hypogonadism 5 with or without anosmia is a genetic condition; lifestyle habits do not cause it but can influence symptoms, bone health, fertility potential, and treatment outcomes. Below are lifestyle risk factors for Hypogonadotropic hypogonadism 5 with or without anosmia that may worsen or ease complications. These suggestions are meant to complement, not replace, medical therapy. Discuss changes with your care team, especially if you are on hormone treatment or fertility regimens.
Weight-bearing and resistance exercise helps rebuild bone density and muscle mass that are reduced by low sex hormones. It can lower fracture risk and improve energy and physical function.
Consistent intake supports bone mineralization when estrogen or testosterone are low. Without it, bone loss and fracture risk can accelerate despite medical therapy.
Obesity can worsen fatigue, reduce testosterone through aromatization, and impair fertility parameters. Underweight and low energy intake can further suppress the reproductive axis and weaken bones.
Regular heavy drinking further suppresses the hypothalamic–pituitary–gonadal axis and can blunt responses to hormone therapy. It also harms sperm quality and raises fracture risk by weakening bone and increasing falls.
Risk prevention
There’s no way to prevent this genetic condition itself, but you can lower the chance of complications and support healthy development across childhood and adulthood. If a close relative is affected, learning the early symptoms of Hypogonadotropic hypogonadism 5 with or without anosmia—such as delayed puberty or reduced sense of smell—can prompt earlier care. Care plans often focus on timely hormone treatment, bone strength, fertility options, and safety for those with reduced smell. Knowing your risks can guide which preventive steps matter most.
A genetics professional can explain inheritance, chances for family members, and testing options. This helps you plan monitoring and care for children who may be affected.
Carrier testing and options like IVF with embryo testing can reduce the chance of passing on the condition. Prenatal testing may be available for those who prefer information during pregnancy.
Watch for delayed or absent puberty and flag it early with a doctor if there’s family history. Early referral to an endocrine specialist can prevent avoidable delays in treatment.
Scheduled visits with an endocrinology team help track growth, puberty progress, and treatment effects. Adjusting care over time reduces risks like low bone density or anemia.
Transmission
Hypogonadotropic hypogonadism 5 with or without anosmia is not contagious—you can’t catch it from someone else. It usually stems from a change in a single gene and is most often passed down in a dominant way (autosomal dominant), meaning a parent with the gene change has a 50% chance of passing it to each child. In many families there’s no prior history because the change happens for the first time in the child (a new mutation), and features can vary—even within the same family—so some may have smell loss while others do not. If you’re wondering how Hypogonadotropic hypogonadism 5 with or without anosmia is inherited in your family, a clinical geneticist or genetic counselor can explain the genetic transmission and discuss testing options.
When to test your genes
Consider genetic testing if puberty is delayed or absent, fertility is reduced, or smell is reduced or missing, especially with a family history of similar findings. Testing can confirm the diagnosis, guide hormone therapy and fertility planning, and identify relatives who may benefit from evaluation. Seek testing before starting long-term hormones when possible.
Diagnosis
For many, the first step comes when everyday activities start feeling harder, like not hitting expected puberty milestones or struggling with fertility later on. Hypogonadotropic hypogonadism 5 with or without anosmia is typically identified by a mix of day-to-day signs and focused testing. The genetic diagnosis of Hypogonadotropic hypogonadism 5 with or without anosmia often combines clinical clues, hormone testing, imaging, and DNA analysis to confirm the cause. Getting a diagnosis is often a turning point toward answers and support.
Doctors look for delayed or absent puberty, such as few or no underarm/pubic hair, small testes, or absent periods. They also review growth patterns, prior health issues, medications, and fertility history.
Levels of LH and FSH are low or inappropriately normal, while sex hormones like testosterone or estradiol are low. This pattern supports a central (brain-based) cause rather than a problem in the ovaries or testes.
Simple bedside smell checks or standardized odor tests look for reduced or absent smell (anosmia/hyposmia). Finding smell loss supports a form that overlaps with Kallmann syndrome, but normal smell can also occur in HH5.
Thyroid, prolactin, iron studies, and inflammatory markers help exclude common causes of low hormones. ... and other lab tests may help rule out common conditions.
Stages of Hypogonadotropic hypogonadism 5 with or without anosmia
Hypogonadotropic hypogonadism 5 with or without anosmia does not have defined progression stages. It typically appears around puberty as a steady problem with the brain’s hormone signals that trigger sexual development, rather than a condition that worsens step by step; a reduced sense of smell may or may not be present. Early symptoms of hypogonadotropic hypogonadism 5 can include delayed or absent puberty, periods not starting, small testes, low libido, and sometimes a poor or absent sense of smell. Different tests may be suggested to help confirm the diagnosis, including blood tests for the puberty hormones (LH and FSH) and sex hormones, a smell assessment, imaging of the brain and olfactory structures, and, in some cases, genetic testing.
Outlook and prognosis
Daily routines often adapt when hypogonadotropic hypogonadism 5 with or without anosmia affects puberty, fertility, energy, and bone health. Many living with this condition do well with treatment, especially when low sex-hormone levels are corrected and fertility care is offered if desired. Early care can make a real difference, helping prevent complications like low bone density and supporting mood and sexual health. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle. Mortality is generally near normal when hormones are replaced appropriately and related health risks—such as osteoporosis—are managed.
Here’s what research and experience suggest about the future. Some people experience early symptoms of hypogonadotropic hypogonadism 5 with or without anosmia in the teen years, while others notice them as adults when periods are absent or fertility is difficult. With ongoing care, many people maintain satisfying sexual function, stable bone health, and, with assisted reproductive options, the chance of pregnancy or biological parenthood. Loss of smell (anosmia) does not change life expectancy, but it can affect safety and enjoyment of food; practical strategies—like smoke detectors and checking expiration dates—help. Not everyone with the same gene change will have the same outlook, and a minority may see partial, sometimes temporary, return of hormone signaling.
Talk with your doctor about what your personal outlook might look like. Plans typically include long-term hormone replacement, periodic bone checks, and tailored fertility treatments when or if you want them. Knowing what to expect can ease some of the worry, and it allows you and your care team to adjust doses, monitor side effects, and address mood, sleep, and intimacy as life evolves.
Long-term effects
Hypogonadotropic hypogonadism 5 with or without anosmia often shapes puberty, fertility, bone health, and day‑to‑day wellbeing over time. Long-term effects vary widely, and they depend on whether smell is affected and how consistently hormones are replaced. Many recall early symptoms of hypogonadotropic hypogonadism 5—such as delayed or absent puberty—before the longer-term picture becomes clear. With the right medical care, many people achieve typical adult development and have a normal life expectancy.
Without hormone therapy, pubertal changes may remain incomplete or absent. With treatment started in adolescence or adulthood, secondary sexual characteristics usually develop over time.
Low sex hormones can lead to low libido, vaginal dryness, or erectile difficulties. Hormone replacement often improves comfort, desire, and sexual function.
Natural fertility is typically reduced without targeted treatment. Medications that stimulate the reproductive glands can enable ovulation or sperm production for many.
If anosmia or reduced smell is present, it usually remains stable lifelong. Smell does not typically improve with hormone therapy.
How is it to live with Hypogonadotropic hypogonadism 5 with or without anosmia?
Daily life with hypogonadotropic hypogonadism 5 can feel like your body’s puberty clock never quite started or never kept pace, which can affect energy, muscle strength, bone health, sexual function, fertility, and—if anosmia is present—your ability to smell and fully enjoy food or detect hazards like smoke. Many balance medical care with practical routines: hormone replacement, calcium/vitamin D and weight‑bearing exercise for bones, planning around clinic visits and labs, and, when desired, fertility treatments that can be time‑intensive but often effective. Relationships can be supportive yet tender territory—open conversations about libido, intimacy, and family planning help partners, family, and friends understand what’s medical, not personal, and how to be helpful. With the right team and treatment plan, most people build active, satisfying lives, adapting as needs change over time.
Treatment and drugs
Treatment for hypogonadotropic hypogonadism 5 with or without anosmia focuses on replacing the hormones the body isn’t making and, when desired, helping with fertility. Daily or periodic sex hormone therapy (testosterone for men; estrogen with progesterone for women) supports puberty changes, bone and muscle health, sexual function, and menstrual cycles. If fertility is a goal, specialists use injectable gonadotropins or a pump that delivers GnRH in pulses to stimulate the ovaries or testes; these approaches are well established and can lead to healthy pregnancies. Doctors sometimes recommend a combination of lifestyle changes and drugs, such as calcium and vitamin D for bone strength, plus monitoring with blood tests and bone scans to adjust dosing over time. Finding the right therapy can take some time, so keep track of how you feel and stay in close contact with your care team.
Non-drug treatment
Living with hypogonadotropic hypogonadism 5 with or without anosmia can touch many parts of daily life—from puberty timing and fertility plans to bone strength and smell safety. For some, early symptoms of hypogonadotropic hypogonadism 5 like delayed puberty can affect confidence at school, work, or in relationships. Alongside medicines, non-drug therapies can improve day-to-day wellbeing, safety, and long-term health. These options can be tailored to your goals and may change over time as needs shift.
A genetics professional can explain the cause, inheritance, and chances for family members. They can also discuss testing options and family planning choices.
Therapy can help with body image, mood, and the stress of delayed puberty or fertility uncertainty. Supportive therapies can also aid communication with partners and family.
A clinician trained in sexual health can guide comfort, intimacy, and consent at any stage of treatment. They can suggest practical tools and strategies that align with your values.
Regular weight-bearing and resistance activities support bone density and muscle strength. This matters because people with hypogonadotropic hypogonadism 5 have higher risk of low bone mass.
Your genes may have an impact on how drugs work for you
Some people process hormone therapies and fertility medicines differently because of inherited differences in liver enzymes and hormone receptors, which can change dose needs or side‑effect risk. Genetic variants tied to smell and GnRH signaling may also influence treatment response and timing.
Pharmacological treatments
Treatment focuses on replacing missing hormones to start puberty, maintain sexual health, and protect bones, and using fertility medicines when pregnancy is desired. Not everyone responds to the same medication in the same way. Options include testosterone or estrogen with progesterone, pulsatile GnRH, and gonadotropin injections; choices depend on age, goals, and test results. These plans can also help with early symptoms of hypogonadotropic hypogonadism 5 with or without anosmia, like delayed puberty and low libido.
Testosterone enanthate or cypionate injections, or transdermal gel/patches, help start and maintain male puberty and sexual function. Dosing is often increased gradually to mimic natural puberty and support muscle, mood, and energy. Regular blood tests track levels and check safety, including blood count and liver profile.
Estradiol pills, patches, or gels start and maintain female puberty and protect bone and heart health. After the uterus has been primed with estrogen, progesterone (such as micronized progesterone) is added to protect the uterine lining and create regular bleeding. Choices depend on age, fertility plans, migraines, and clotting risk.
Gonadorelin given by a small pump in pulses can restore the brain-to-pituitary signaling needed for ovulation or sperm production. It is most helpful when the pituitary responds normally on testing. This option aims for more natural hormone rhythms and may reduce the need for frequent monitoring compared with high-dose injections.
Human chorionic gonadotropin (hCG) with recombinant FSH (follitropin alfa) or menotropins (hMG) can trigger sperm production in men over months. In women, FSH with LH (e.g., lutropin alfa) or hMG stimulates follicle growth and ovulation, often with ultrasound monitoring. These are fertility-focused treatments and paused when pregnancy is not being pursued.
Genetic influences
Genetics plays a central role by shaping how the brain’s hormone “starter signal” develops and works. In Hypogonadotropic hypogonadism 5 with or without anosmia, changes in certain genes can disrupt the development or function of the GnRH nerve cells that trigger puberty and, in some people, the smell pathways, which is why some have a reduced or absent sense of smell while others do not. These gene effects help explain why early symptoms of Hypogonadotropic hypogonadism 5 with or without anosmia often show up around puberty, when the body expects stronger hormone signals.
Inheritance can vary: some families pass the condition on from one parent, others when both parents carry a silent change, and sometimes it appears for the first time in a family due to a new change. Having a gene change doesn’t always mean you will develop the condition. In some people, more than one gene contributes, which can shift how severe the hormone shortage is and whether smell is affected. Genetic testing may find the underlying change in a known gene, though not in every case, and results can help tailor care and inform risks for relatives.
Is Hypogonadotropic hypogonadism 5 with or without anosmia genetic?
Genetics play a central role in hypogonadotropic hypogonadism 5 with or without anosmia. Inherited variants in specific genes disrupt hormone signals that trigger puberty and fertility. Patterns vary by gene; some families show autosomal dominant, recessive, or X-linked inheritance.
Pharmacogenetics—how genetics influence drug effects
The specific gene involved can shape treatment choices in hypogonadotropic hypogonadism 5 with or without anosmia, especially when planning fertility therapy. If the main issue is the brain signal that starts puberty, many respond well to a small pump that delivers this hormone in pulses; but if the pituitary’s receptors are the problem, that approach won’t help and doctors use lab-made gonadotropins (LH/FSH) instead to stimulate the ovaries or testes. Genetic testing can sometimes identify how your body is likely to respond to pulsatile GnRH versus gonadotropin injections. Day-to-day hormone replacement—testosterone for males or estrogen with progesterone for females—is usually adjusted by symptoms, blood tests, and side effects rather than by genotype, so routine drug‑metabolism testing isn’t part of treatment options for hypogonadotropic hypogonadism 5 with or without anosmia. In fertility care, common differences in gonadotropin receptor genes can influence how strong the ovarian or testicular response is and may affect dose needs, but this pharmacogenetic testing isn’t standard practice today. Knowing the underlying gene can also hint at the chance of later “reversal” of the body’s own hormone signaling, helping clinicians decide when a carefully supervised pause or switch in therapy might be reasonable.
Interactions with other conditions
People living with Hypogonadotropic hypogonadism 5 with or without anosmia often have other health issues that can influence how their symptoms feel day to day. Doctors call it a “comorbidity” when two conditions occur together. Extra body weight, insulin resistance, or type 2 diabetes can lower sex hormone levels further, so fatigue, low libido, and menstrual or erectile problems may feel more pronounced; in turn, untreated low estrogen or testosterone can make weight gain and cholesterol changes harder to manage. Thyroid or adrenal disorders, high prolactin, and sleep apnea can also blur the picture and sometimes worsen delayed puberty or fertility challenges; some medications, like long-term opioids or steroids, have similar suppressive effects on the hormone signals. For many, bone health is a shared concern—low sex hormones increase the risk of low bone density and fractures, especially if vitamin D is low or if there’s limited weight-bearing activity. Early symptoms of Hypogonadotropic hypogonadism 5 with or without anosmia can overlap with signs of other conditions (for example, hypothyroidism or chronic undernutrition), which is why coordinated care and clear testing matter.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described delayed or absent puberty without clear cause, often noting that some relatives shared the same pattern. Families and communities once noticed patterns like boys who never needed to shave or girls whose periods never began, while others in the family developed normally. In some stories, a poor sense of smell showed up alongside these changes, though the connection wasn’t obvious at the time.
First described in the medical literature as a form of delayed puberty linked to low hormones from the brain, this condition later became known in genetics as hypogonadotropic hypogonadism 5 with or without anosmia. Early reports focused on visible features—shorter growth spurts, little body hair, testicles or ovaries that did not “switch on” in adolescence—because hormone tests and brain imaging were not yet available. As endocrinology grew in the mid-20th century, researchers recognized that the pituitary and hypothalamus act like a paired signaling system; when the signal (GnRH) is weak or disrupted, sex hormones remain low. Some people also had a reduced or absent sense of smell (anosmia), hinting that shared developmental pathways might be involved.
From these first observations, the story moved into the genetics era. In recent decades, awareness has grown that what looked like one disorder is actually a group of related conditions with many gene changes, including forms where smell is normal. Researchers mapped inheritance in large families, then used gene sequencing to pinpoint variants that affect the brain’s hormone-releasing neurons and, in some, the nerve pathways for smell. The label “with or without anosmia” reflects this variability: many living with hypogonadotropic hypogonadism 5 share the same core issue—insufficient hormone signaling from the brain—but differ in smell function and in how early or severely symptoms appear.
Over time, descriptions became more precise. Doctors learned that early symptoms of hypogonadotropic hypogonadism 5 can be subtle in childhood—fewer growth spurts, undescended testes in some boys, or a later-than-expected start to puberty—and that features seen by clinicians include low sex hormone levels with otherwise typical pituitary tests. Genetic testing then linked certain patterns within families, confirming that some cases are inherited while others arise for the first time in an individual.
These historical steps shaped care. What once required years of watchful waiting can now be identified earlier with hormone testing and, when appropriate, genetic evaluation. Knowing the condition’s history helps explain why smell testing, family history, and careful hormone measurements still matter today, and why treatment plans are tailored—some people benefit from hormone replacement to induce puberty and support bone and heart health, while others may consider fertility treatments later on. Despite evolving definitions, the central insight has remained steady: strengthening the brain-to-gland signal can restore many day-to-day functions that puberty would otherwise provide.